Your browser doesn't support javascript.
loading
A stable, engineered TL1A ligand co-stimulates T cells via specific binding to DR3.
Zwolak, Adam; Chan, Szeman Ruby; Harvilla, Paul; Mahady, Sally; Armstrong, Anthony A; Luistro, Leopoldo; Tamot, Ninkka; Yamada, Douglas; Derebe, Mehabaw; Pomerantz, Steven; Chiu, Mark; Ganesan, Rajkumar; Chowdhury, Partha.
Afiliação
  • Zwolak A; Biologics Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA. azwolak1@its.jnj.com.
  • Chan SR; Oncology Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
  • Harvilla P; Biologics Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
  • Mahady S; Oncology Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
  • Armstrong AA; Biologics Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
  • Luistro L; Oncology Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
  • Tamot N; Biologics Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
  • Yamada D; Oncology Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
  • Derebe M; Merck Research Laboratories, Discovery Biologics, Protein Sciences, South San Francisco, CA, USA.
  • Pomerantz S; Biologics Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
  • Chiu M; Tavotek Biotherapeutics, Spring House, PA, USA.
  • Ganesan R; Immunotherapeutics, Amgen, South San Francisco, CA, USA.
  • Chowdhury P; Cell Engineering and Early Development, Janssen Research & Development, Spring House, PA, USA.
Sci Rep ; 12(1): 20538, 2022 11 29.
Article em En | MEDLINE | ID: mdl-36446890
ABSTRACT
TL1A (TNFSF15) is a TNF superfamily ligand which can bind the TNFRSF member death receptor 3 (DR3) on T cells and the soluble decoy receptor DcR3. Engagement of DR3 on CD4+ or CD8+ effector T cells by TL1A induces downstream signaling, leading to proliferation and an increase in secretion of inflammatory cytokines. We designed a stable recombinant TL1A molecule that (1) displays high monodispersity and stability, (2) displays the ability to activate T cells in vitro and in vivo, and (3) lacks binding to DcR3 while retaining functional activity via DR3. Together these results suggest the TL1A ligand can be amenable to therapeutic development on its own or paired with a tumor-targeting moiety.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T / Membro 15 da Superfamília de Ligantes de Fatores de Necrose Tumoral Idioma: En Revista: Sci Rep Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T / Membro 15 da Superfamília de Ligantes de Fatores de Necrose Tumoral Idioma: En Revista: Sci Rep Ano de publicação: 2022 Tipo de documento: Article